PROPEL 2

Clinical Trial · Infigratinib · PROPEL · QED Therapeutics

BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA

09.17.2024 at 7:30 AM EDT – Breakthrough Therapy Designation was granted based on preliminary clinical evidence from the PROPEL 2 clinical trial, meeting the FDA’s requirement of potentially demonstrating substantial…

Read More BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA
ACCEL · Achondroplasia · Clinical Trial · Infigratinib · PROPEL · QED Therapeutics

BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia

SOURCE: Bridge Bio, Inc. QED Therapeutics, an affiliate company of BridgeBio, is an Emerald Sponsor of this year’s Achondroplasia & Skeletal Dysplasia Research Conference, June 28-30 in Baltimore, Maryland. This…

Read More BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia
Achondroplasia · Hypochondroplasia · Infigratinib · PROPEL · QED Therapeutics

BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan

SOURCE: BRIDGEBIO.COM/NEWS – BridgeBio grants Kyowa Kirin exclusive license to develop and commercialize infigratinib for skeletal dysplasias in Japan – BridgeBio to receive upfront payment of USD 100 million with…

Read More BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
Hypochondroplasia · Infigratinib · PROPEL · QED Therapeutics

BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual Conference

The following press release was obtained from BridgeBio.com, parent company of QED therapeutics. To learn more about QED and their research surrounding achondroplasia and other skeletal dysplasias, click here. PALO ALTO, Calif., June…

Read More BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual Conference

translate 🔁